Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety monitoring study of Naoxintong capsule
ChiCTR-OPC-17013912Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Jan 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naoxintong in adverse drug reaction (ADR) and adverse drug event (ADE), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: Adverse drug reactions/adverse drug events. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
naoxintong
03
Conditions
adverse drug reaction (ADR)adverse drug event (ADE)
Beyond the preview
Go deeper on ChiCTR-OPC-17013912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013912.